论文部分内容阅读
目的比较MVP方案与CAP方案治疗晚期非小细胞肺癌的疗效和不良反应。方法MVP组38例,MMC6mg/m2静脉注射,第1天;VDS3mg/m2静脉注射,第1、8天;DDP30mg/m2静脉滴注第1～3天。CAP组37例,CTX600mg/m2静脉注射,第1天;ADM或Epi-ADM40mg/m2静脉注射,第1天;DDP30mg/m2静脉滴注第1～3天,21天为1个周期,连用2个周期后进行疗效评估。结果MVP组CR3例,PR14例,总有效率44.7%;CAP组CR1例,PR12例,总有效率35.1%。两组不良反应主要为恶心、呕吐和骨髓抑制,CAP组恶心、呕吐程度较MVP组严重(P<0.05)。结论采用MVP方案治疗晚期非小细胞肺癌的有效率高,不良反应可以耐受,价格适中,可作为临床治疗NSCLC的一线方案。
Objective To compare the efficacy and side effects of MVP and CAP in the treatment of advanced non-small cell lung cancer. Methods MVP group 38 cases, MMC6mg / m2 intravenous injection, on the first day; VDS3mg / m2 intravenous injection, on the first and eighth days; DDP30mg / m2 intravenous drip 1 to 3 days. CAP group 37 cases, CTX600mg / m2 intravenous injection on day 1; ADM or Epi-ADM40mg / m2 intravenous injection on day 1; DDP30mg / m2 intravenous infusion of 1 to 3 days, 21 days for a cycle, even with 2 After a period of efficacy evaluation. Results In MVP group, 3 cases were CR and 14 cases were PR, the total effective rate was 44.7%. In CR group, 1 case was CR1, and 12 cases were PR. The total effective rate was 35.1%. The two groups of adverse reactions were mainly nausea, vomiting and myelosuppression. The nausea and vomiting in CAP group were more serious than those in MVP group (P <0.05). Conclusions The MVP regimen is effective in treating advanced non-small cell lung cancer (NSCLC). Adverse reactions can be tolerated and moderately priced. It can be used as a first-line regimen for the treatment of NSCLC.